World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
35140
World Ranking
12994
National Ranking
6643

Overview

Kenneth B. Gordon is affiliated with the Medical College of Wisconsin in the United States. Their research primarily focuses on the field of Medicine, with a significant emphasis on Immunology and Microbiology. Subfields of study include Immunology, Dermatology, Pathology and Forensic Medicine, Oncology, and Economics and Econometrics.

The main topics of research undertaken by Kenneth B. Gordon center on Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Studies and Practices, Cytokine Signaling Pathways and Interactions, and Asthma and Respiratory Diseases.

Recent notable publications featuring Kenneth B. Gordon include:

  • Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial, 2021, The Lancet
  • Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies, 2020, Journal of the American Academy of Dermatology
  • Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures, 2020, Journal of the American Academy of Dermatology
  • Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial, 2021, The Lancet
  • Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial, 2022, Journal of the American Academy of Dermatology

Frequent collaborators in Kenneth B. Gordon's research include:

  • Diamant Thaçi
  • Mark Lebwohl
  • Bruce Strober
  • Kim Papp
  • Andrew Blauvelt

Kenneth B. Gordon has contributed substantially to several scientific journals. The most frequent publication venues are:

  • Journal of the American Academy of Dermatology
  • SKIN The Journal of Cutaneous Medicine
  • Dermatology and Therapy
  • British Journal of Dermatology
  • JAMA Dermatology

Best Publications

  • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

    Craig L Leonardi;Alexa B Kimball;Kim A Papp;Newman Yeilding

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

    Alan Menter;Alice Gottlieb;Steven R. Feldman;Abby S. Van Voorhees

  • Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

    Stephen Tyring;Alice Gottlieb;Kim Papp;Ken Gordon

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics

    Alice Gottlieb;Neil J. Korman;Kenneth B. Gordon;Steven R. Feldman

  • Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Alan Menter;Stephen K. Tyring;Kenneth Gordon;Alexa B. Kimball

  • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

    Alan Menter;Bruce E. Strober;Daniel H. Kaplan;Dario Kivelevitch

  • Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Mark Lebwohl;Bruce Strober;Alan Menter;Kenneth Gordon

  • Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Kenneth B Gordon;Jean-Frederic Colombel;Dana S Hardin

  • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.

    Kristian Reich;April W. Armstrong;Peter Foley;Michael Song

  • Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis. Section 3. Guidelines of Care for the Management and Treatment of Psoriasis With Topical Therapies

    Alan Menter;Neil J. Korman;Craig A. Elmets;Steven R. Feldman

  • Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

    Kenneth B. Gordon;Richard G. Langley;Craig Leonardi;Darryl Toth

  • Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

    Gerd R Burmester;Remo Panaccione;Kenneth B Gordon;Melissa J McIlraith

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

    Alan Menter;Neil J. Korman;Craig A. Elmets;Steven R. Feldman

  • Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Kim Papp;Kristian Reich;Craig L. Leonardi;Leon Kircik

  • A Randomized Trial of Etanercept as Monotherapy for Psoriasis

    Alice B. Gottlieb;Robert T. Matheson;Nicholas Lowe;Gerald G. Krueger

  • Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    Kenneth B Gordon;Bruce Strober;Mark Lebwohl;Matthias Augustin

  • National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

    Alexa B. Kimball;Dafna Gladman;Joel M. Gelfand;Kenneth Gordon

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

    Alan Menter;Neil J. Korman;Craig A. Elmets;Steven R. Feldman

  • Efalizumab for Patients with Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial

    Kenneth B. Gordon;Kim A. Papp;Tiffani K. Hamilton;Patricia A. Walicke

  • Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

    K A Papp;C E M Griffiths;K Gordon;M Lebwohl

Frequent Co-Authors

Craig L. Leonardi
Craig L. Leonardi Saint Louis University
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Kim Papp
Kim Papp Probity Medical Research
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Alan Menter
Alan Menter Texas A&M University
Richard G. Langley
Richard G. Langley Dalhousie University
Alexa B. Kimball
Alexa B. Kimball Beth Israel Deaconess Medical Center
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Kristian Reich
Kristian Reich University of Göttingen
Gerald G. Krueger
Gerald G. Krueger University of Utah

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in Medicine, you’ll find many related online degrees that open diverse opportunities in healthcare. For those interested in patient care but looking for flexible entry requirements, consider enrolling in a nursing school that does not require teas test. These programs allow aspiring nurses to start their education without the added stress of standardized admissions tests.

If you’re drawn to leadership and hospital management, exploring healthcare administration degrees provides a pathway to non-clinical roles that are crucial for the effective running of healthcare facilities.

Current registered nurses seeking career advancement may benefit from specialized bridge programs, such as adn to np bridge programs, which streamline the track to becoming a nurse practitioner.

For those passionate about preventive health and wellbeing, an online nutrition degree can lead to exciting roles in dietetics, coaching, or community health.

Each of these online degree options supports flexible learning and broadens your career possibilities within the evolving field of healthcare.

Best Scientists Citing Kenneth B. Gordon

Trending Scientists

Recently Published Articles